FDA Brief

Warning letters Drugs

FDA warning letter to

Swisschems

High riskIssued Dec 10, 2024Posted Dec 17, 2024Center for Drug Evaluation and Research (CDER)

Swisschems sells Semaglutide and Retatrutide as unapproved new drugs despite research-chemical labeling.

What happened

FDA reviewed the Swisschems website in October 2024 and the company’s Facebook and Instagram pages. It found Semaglutide and Retatrutide offered for sale in the U.S., with claims that FDA said showed the products were intended as drugs for human use despite “research chemicals only” labeling. FDA said no approved applications were in effect for the products.

What FDA found

  1. Swisschems offered Semaglutide for sale without an FDA-approved application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. Swisschems offered Retatrutide for sale without an FDA-approved application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  3. Website and social media claims made clear the products were intended as drugs for human use, despite “research chemicals only” labeling.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  4. FDA treated the products as new drugs not generally recognized as safe and effective for the claimed uses.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  5. No approved applications were in effect for these products.

    FD&C Act section 505, 21 U.S.C. 355

What FDA wants

FDA tells Swisschems to notify it in writing within fifteen working days of the specific steps taken to correct the violations and prevent recurrence, with supporting documentation. If corrective action cannot be completed in that time, the company must state why and give a completion date.

Who should pay attention

  • companies selling research chemicals online
  • brands marketing GLP-1 or weight-loss products
  • quality teams reviewing online product claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk